| Literature DB >> 19104842 |
Bernd Hoppe1, Markus J Kemper.
Abstract
Urolithiasis and nephrocalcinosis are more frequent in children then currently anticipated, but still remain under- or misdiagnosed in a significant proportion of patients, since symptoms and signs may be subtle or misleading. All children with colicky abdominal pain or macroscopic hematuria should be examined thoroughly for urolithiasis. Also, other, more general, abdominal manifestations can be the first symptoms of renal stones. The patients and their family histories, as well as physical examination, are important initial steps for diagnostic evaluation. Thereafter, diagnostic imaging should be aimed at the location of calculi but also at identification of urinary tract anomalies or acute obstruction due to stone disease. This can often be accomplished by ultrasound examination alone, but sometimes radiological methods such as plain abdominal films or more sensitive non-enhanced computed tomography are necessary. Since metabolic causes are frequent in children, diagnostic evaluation should be meticulous so that metabolic disorders that cause recurrent urolithiasis or even renal failure, such as the primary hyperoxalurias and others, can be ruled out. The stone is not the disease itself; it is only one serious sign! Therefore, thorough and early diagnostic examination is mandatory for every infant and child with the first stone event, or with nephrocalcinosis.Entities:
Mesh:
Year: 2008 PMID: 19104842 PMCID: PMC2810372 DOI: 10.1007/s00467-008-1073-x
Source DB: PubMed Journal: Pediatr Nephrol ISSN: 0931-041X Impact factor: 3.714
Diagnostic steps in urolithiasis (UTI urinary tract infection, CT computed tomography, MRI magnetic resonance imaging, PTH parathyroid hormone, pCO partial pressure of carbon dioxide)
| Step | Diagnostic findings |
|---|---|
| History, including family history | Diet, fluid intake, medication, vitamin supplementation |
| Chronic diseases? Malabsorption syndromes? | |
| Immobilization? | |
| Clinical findings | Pain, hematuria, vomiting, UTI |
| Passage of stones, gravel | |
| Imaging | Ultrasonography, (plain film) |
| Non-contrast-enhanced CT, (MRI) | |
| (Intravenous urography) | |
| Urine | Density, specific gravity (osmolality), pH, glucose, protein, sediment, culture |
| Spot urine: molar creatinine ratios of calcium, oxalate, uric acid, citrate, magnesium | |
| Cystine screening (nitroprusside test, amino acid screen) | |
| 24 hour urine: volume, pH; (lithogenic and stone-inhibitory parameters); calculation of urinary saturation | |
| Blood/serum | Electrolytes, calcium, phosphorus, magnesium, creatinine, urea, uric acid, alkaline phosphatase, (PTH, vitamins D/A, plasma oxalate, serum vitamin B6 level) |
| Acid-base status (pH, pCO2, base excess and/or standard bicarbonate) | |
| Stone analysis | Infrared spectroscopy or X-ray diffraction |
Disorders of special interest presenting with urolithiasis and/or nephrocalcinosis. For further information see other chapters of the teaching series on urolithiasis in childhood. MIM Mendelian inheritance in man (catalogue no.), HPRT hypoxanthine-guanine-phosphoribosyl transferase, APRT adenine phosphoribosyltransferase, dRTA distal renal tubular acidosis, AD autosomal dominant, AR autosomal recessive, XLR, X linked recessive, LMW low molecular weight, CRF chronic renal failure
| MIM | Locus, gene | Inheritance | Gene product | Phenotype | |
|---|---|---|---|---|---|
| Autosomal dominant hypocalcemic hypercalciuria | 146200; 601199 | 3q13.3- q21, CASR | AD | CASR | Hypercalciuria |
| Hypocalcemia | |||||
| CRF | |||||
| Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) | 248250; 603959 | 3q27, 1p34.2, CLDN16, CLDN 19 | AR | Paracellin 1, (Claudin 16, 19) | Hypercalciuria, hypercalcemia, hypomagnesemia, dRTA, CRF, hypermagnesuria, polyuria, tetany seizures |
| Dent’s disease, (Dent 1) | 300009; 310468; 300008 | Xp11.22, CLCN5 | XLR | CLC-5 | Hypercalciuria, renal phosphate leak (variable), LMW proteinuria, hypophosphatemia (variable) |
| Lowe syndrome, (Dent 2) | 309000 | Xq.25-26, OCRL1 | XLR | OCRL1 protein | Hypercalciuria, megalin deficiency, phosphate leak, Fanconi syndrome |
| Bartter’s syndrome type 1 | 600839 | 15q15-q21.1, NKCC2 | AR | SLC12A1 | Salt wasting, hypokalemic metabolic alkalosis, and hypercalciuria, nephrocalcinosis |
| Bartter’s syndrome type 2 | 600359 | 11q24, ROMK | AR | KCNJ1 | Salt wasting, hypokalemic metabolic alkalosis, and hypercalciuria, nephrocalcinosis |
| Infantile Bartter’s syndrome with sensorineural deafness | 602522; 606412; 602024; 602023 | 1p31, 1p36, BSND CLCNKB | AR | Salt wasting, hypokalemic metabolic alkalosis, and hypercalciuria, nephrocalcinosis | |
| Williams–Beuren syndrome | 194050; 130160; 601329; 600404 | contiguous gene deletion syndrome 7q11.23, ELN, LIMK1, RFC2 | AD | Elastin, LIM-kinase 1 | Hypercalcemia, hypercalciuria, mental retardation ‘happy party manner’, aortic stenosis, ‘Elfin-faces’, nephrocalcinosis |
| Nephrolithiasis and osteoporosis associated with hypophosphatemia due to mutation in the type 2 sodium phosphate co-transporter | 182309 | 5q.35 | Unknown | NPTZa | Renal phosphate leak, hypercalciuria, osteoporosis, ↑ 1,25 dihydroxy-vitamin D |
| Primary hyperoxaluria, type I | 259900; 604285 | 2q.37.3, AGXT | AR | AGT | Hyperoxaluria, hyperglycolic aciduria, CRF, systemic oxalosis |
| Primary hyperoxaluria, type II | 260000; 604296 | 9q.11, GRHPR | AR | GR/HPR | Hyperoxaluria, |
| Cystinuria type A | 104614 | 2p q.16.3, SLC3A1 | AR | r BAT | Elevated urinary excretion of cystine (and other dibasic amino acids) |
| Urine microscopy: hexagonal cystine crystals, recurrent urolithiasis, (CRF) | |||||
| Cystinuria type B | 604144 | 19 q.13.1/SLC7A9 | Inc AR | B α + AT | Elevated urinary excretion of cystine (and other dibasic amino acids) |
| Urine microscopy: hexagonal cystine crystals, recurrent urolithiasis, (CRF) | |||||
| Cystinuria type A/B | 220100 | SLC3A1/SLC7A1 | |||
| Lesch–Nyhan syndrome | 300322 | Xq26, HPRT | XLR | HPRT | Hyperuricosuria, gout, automutilation, recurrent urolithiasis |
| Partial HPRT deficiency | 308000 | Xq.26–27.2, HPRT | XLR | HPRT | Hyperuricosuria |
| Glycogenosis type 1a | 232200 | 17q.21, G6PC | AR | Glucose-6-phosphatase | Hyperuricosuria |
| Glycogenosis type 1b | 232220 | 11q.23, SLC37A4 | AR | Transporter | Hyperuricosuria |
| Phosphoribosylphosphate synthetase 1 superactivity | 311850 | Xq21, PRPS1 | XL | Hyperuricosuria | |
| APRT deficiency | 102600 | 16q.24.3, APRT | AR | APRT | 2,8 Dihydroxy-adeninuria, recurrent crystalluria (round + brown), urolithiasis (radiolucent), rarely renal failure from crystal nephropathy |
| Xanthinuria (classical) | 278300 | 2p.22, XDH | AR | Xanthine oxydoreductase or dehydrogenase | Xanthinuria, hypouricemia |
| Renal tubular acidosis autosomal dominant | 179800; 109270 | 17q.21–q.22, SLC4A1, AE1 | AD | AE1 | Hypocitric aciduria, hypercalciuria, hypokalemia, osteomalacia |
| Autosomal recessive dRTA with hearing loss | 267300; 192132 | 2cen-q13, ATP6B1 | AR | B1 | Hypercalciuria, hypocitric aciduria, hypokalemia, rickets, hearing loss |
| Autosomal recessive dRTA | 602722; 605239 | 7q.33-34, SLC4A1 | AR | A4 | Hypercalciuria, hypocitric aciduria, hypokalemia |
Fig. 1a Normal, still hyperechoic kidney of a preterm infant; b Tamm–Horsfall kidney; c medullary nephrocalcinosis (NC) grade I (mild increase of echogenicity around the pyramidal border); d medullary NC grade II (mild increase of echogenicity at whole pyramid); e medullary NC grade III (more severe hyperechogenicity of entire pyramid); f diffuse corticomedullary NC [6]
Normal values for 24 h urine collection (there should be preservative in the container, either thymol 5% in isopropanol, or 2 N hydrochloric acid (HCL), before collection is started). Repeat collection after stone has been captured, as ongoing stone formation may diminish lithogenic excretion parameters. Check urine volume and creatinine excretion (2 mg/kg ± 0.8 mg) to ensure adequate collection [5, 6, 36–41]
| Parameter age | Normal value per 24 h | Remarks |
|---|---|---|
| Calcium, all ages | <0.1 mmol (<4 mg)/kg | See Table |
| Oxalate | <0.5 mmol (<45 mg)/1.73 m2 | Primary hyperoxaluria types I/II for constant excessive elevation, check also urinary glycolate, |
| Secondary hyperoxaluria: determine intestinal oxalate absorption and stool. | ||
| Citrate | ||
| Male | >1.9 mmol (365 mg)/1.73 m2 | Hypocitraturia: metabolic acidosis, hypokalemia, calcineurin inhibitors |
| Female | >1.6 mmol (310 mg)/1.73 m2 | |
| Uric acid, all ages | <.56 mg/dl per GFR | Hyperuricosuria = > check diet, medication, tumor lysis, inborn errors of metabolism |
| Magnesium | >0.04 mmol (0.8 mg)/kg | FFHNC with hypomagnesemia and elevated FEMg, See Table |
| Phosphate | TmP/GFR | Renal phosphate leakage with low serum phosphate, tumor lysis syndrome with high serum phosphate |
| <3 months | <3.3 mmol/l | |
| <6 months | <2.6 mmol/l | |
| 2–15 years | <2.44 mmol/l | |
| Cystine | ||
| <10 years | <55 μmol (13 mg) /1.73 m2 | Check morning urine for hexagonal crystals |
| >10 years | <200 (48 mg) | |
| Adults | <250(60 mg) | |
| Cystine solubility threshold 160–320 mg cystine/l at ph 5–7 | ||
Normal values for spot urine samples: creatinine ratios (solute/creatinine). Ratios are more prone to error than are timed samples. Interpret with respect to daytime, relation to meals, diet, medication, age and regional differences [5, 6, 36–41] (Ca calcium, RTA renal tubular acidosis)
| Parameter age | Ratio of solute to creatinine | Remarks | |
|---|---|---|---|
| Calcium | mol/mol | mg/mg | Highest Ca excretion with breast milk feeding, ratio increasing after meals (up to 40%), by loop diuretics, immobilization and steroids |
| <12 months | <2 | 0.81 | |
| 1–3 years | <1.5 | 0.53 | |
| 1–5 years | <1.1 | 0.39 | |
| 5–7 years | <0.8 | 0.28 | |
| >7 years | <0.6 | 0.21 | |
| Oxalate | mmol/mol | mg/g | Primary hyperoxaluria types I/II for constant excessive elevation, check also urinary glycolate, |
| 0–6 months | <325–360 | 288–260 | |
| 7–24 months | <132−174 | 110−139 | |
| 2−5 years | <98−101 | 80 | |
| 5−14 years | <70−82 | 60−65 | |
| >16 years | <40 | 32 | |
| Citrate | mol/mol | g/g | Low with tubular dysfunction: RTA, prematurity, hypokalemia, renal transplantation |
| 0–5 years | >0.25 | 0.42 | |
| >5 years | >0.15 | 0.25 | |
| Magnesium | mol/mol | g/g | For <2 years, no reliable data |
| >0.63 | > 0.13 | ||
| Uric acid >2 years | <0.56 mg/dl (33 μmol/l) per GFR | Higher than in adults throughout childhood; no reliable data for age <2 years | |
| (ratio × plasma creatinine) | |||
Ten take-home messages
| Message |
|---|
| 1. Kidney stones/nephrocalcinosis in children are the symptoms of a disease, not the disease itself |
| 2. About 40% of children with urolithiasis have a positive family history |
| 3. Predisposing causes for urolithiasis can be recognized in 75% of children and adolescents |
| 4. Unexplained sterile pyuria or recurrent UTI should raise the suspicion for urolithiasis |
| 5. Gross hematuria may precede manifest urolithiasis or nephrocalcinosis |
| 6. Nephrocalcinosis is mostly asymptomatic |
| 7. The diagnosis of primary hyperoxaluria is often delayed; early detection may prevent the development of renal failure |
| 8. Calyceal depositions of Tamm–Horsfall protein are harmless, but they may mimic nephrocalcinosis in (preterm) neonates |
| 9. Metabolic urine analysis should be performed in 24 h urine collection |
| 10. Passing stone fragments and UTI may hamper proper metabolic urine analysis |